RhumbLine Advisers’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.42M | Buy |
81,261
+11,495
| +16% | +$201K | ﹤0.01% | 2070 |
|
|
2025
Q1 | $878K | Buy |
69,766
+4,603
| +7% | +$57.9K | ﹤0.01% | 2238 |
|
|
2024
Q4 | $687K | Buy |
65,163
+1,824
| +3% | +$19.2K | ﹤0.01% | 2462 |
|
|
2024
Q3 | $918K | Sell |
63,339
-2,603
| -4% | -$37.7K | ﹤0.01% | 2306 |
|
|
2024
Q2 | $561K | Buy |
65,942
+28,888
| +78% | +$246K | ﹤0.01% | 2592 |
|
|
2024
Q1 | $379K | Buy |
37,054
+726
| +2% | +$7.42K | ﹤0.01% | 2832 |
|
|
2023
Q4 | $199K | Sell |
36,328
-27
| -0.1% | -$148 | ﹤0.01% | 3192 |
|
|
2023
Q3 | $137K | Buy |
36,355
+1,924
| +6% | +$7.27K | ﹤0.01% | 3350 |
|
|
2023
Q2 | $231K | Buy |
+34,431
| New | +$231K | ﹤0.01% | 3165 |
|
|
2022
Q2 | – | Sell |
-24,075
| Closed | -$85K | – | 3226 |
|
|
2022
Q1 | $85K | Buy |
24,075
+2,833
| +13% | +$10K | ﹤0.01% | 2920 |
|
|
2021
Q4 | $141K | Buy |
21,242
+1,229
| +6% | +$8.16K | ﹤0.01% | 2897 |
|
|
2021
Q3 | $200K | Buy |
20,013
+3,333
| +20% | +$33.3K | ﹤0.01% | 2916 |
|
|
2021
Q2 | $515K | Buy |
16,680
+3,491
| +26% | +$108K | ﹤0.01% | 2556 |
|
|
2021
Q1 | $575K | Buy |
+13,189
| New | +$575K | ﹤0.01% | 2424 |
|